ACCD Accolade
- 6.595
- +0.035+0.53%
Accolade News
Is Accolade (NASDAQ:ACCD) Using Debt Sensibly?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it seems
Observe.AI Launches Next-Gen Conversation Intelligence, Creating a Definitive Path to Value Realization For Generative AI in Contact Centers
New GenAI enhancements to Real-Time AI and Post-Interaction AI help contact center leaders rapidly drive value with effortless configurability and fast implementationSAN FRANCISCO--(BUSINESS WIRE)--Ob
Accolade To Present at William Blair Growth Stock Conference
PDF Version SEATTLE, May 29, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the William Blair Growth Stock Conference in Chicago on Tuesday,
Truist Financial Maintains Accolade(ACCD.US) With Buy Rating
Truist Financial analyst Jailendra Singh maintains $Accolade(ACCD.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 33.0% and a total average return of -15.2% over t
Accolade Welcomes Noom to Trusted Partner Ecosystem
PDF Version The partnership combines Noom's best-in-class content and coaching with Accolade's advanced primary care physicians SEATTLE, May 21, 2024 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD)
Accolade Price Target Cut to $13.00/Share From $17.00 by Guggenheim
Accolade Price Target Cut to $13.00/Share From $17.00 by Guggenheim
Accolade Is Maintained at Buy by Guggenheim
Accolade Is Maintained at Buy by Guggenheim
Guggenheim: Maintaining the Accolade (ACCD.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $17.00 to $13.00.
Guggenheim: Maintaining the Accolade (ACCD.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $17.00 to $13.00.
Guggenheim Maintains Buy on Accolade, Lowers Price Target to $13
Guggenheim analyst Sandy Draper maintains Accolade (NASDAQ:ACCD) with a Buy and lowers the price target from $17 to $13.
Accolade Is Maintained at Equal-Weight by Wells Fargo
Accolade Is Maintained at Equal-Weight by Wells Fargo
Wells Fargo: Maintaining the Accolade (ACCD.US) rating, adjusted from a wait-and-see shareholding rating to a shareholding wait-and-see rating, and the target price was adjusted from $12.00 to $10.00.
Wells Fargo: Maintaining the Accolade (ACCD.US) rating, adjusted from a wait-and-see shareholding rating to a shareholding wait-and-see rating, and the target price was adjusted from $12.00 to $10.00.
Wells Fargo Maintains Equal-Weight on Accolade, Lowers Price Target to $10
Wells Fargo analyst Stan Berenshteyn maintains Accolade (NASDAQ:ACCD) with a Equal-Weight and lowers the price target from $12 to $10.
Accolade, Inc.'s (NASDAQ:ACCD) Latest 14% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures
Key Insights Significantly high institutional ownership implies Accolade's stock price is sensitive to their trading actions 54% of the business is held by the top 8 shareholders Analyst forecast
EDIT, CLNE and NIU Are Among After Hour Movers
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Aon plc (NYSE:AON) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Aon posted adjusted earnings of $5.66 per share, missing ma
Earnings Call Summary | Accolade(ACCD.US) Q4 2024 Earnings Conference
The following is a summary of the Accolade, Inc. (ACCD) Q4 2024 Earnings Call Transcript:Financial Performance:Accolade Inc. reported Q4 revenue of $125 million, a 30% pro forma growth over the same p
Morgan Stanley Trims Accolade's Price Target to $12 From $13, Maintains Equal Weight Rating
Accolade (ACCD) has an average rating of outperform and price targets ranging from $10 to $18, according to analysts polled by Capital IQ. Price: 7.92, Change: -1.27, Percent Change: -13.82
12 Health Care Stocks Moving In Friday's Intraday Session
GainersBiodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 61.4% to $1.17 during Friday's regular session. The company's market cap stands at $5.1 million. Agenus (NASDAQ:AGEN) shares rose 32.53% to $11.
Accolade Price Target Cut to $11.00/Share From $13.00 by Barclays
Accolade Price Target Cut to $11.00/Share From $13.00 by Barclays
Barclays: Maintaining the Accolade (ACCD.US) rating, adjusted from a wait-and-see shareholding rating to a shareholding wait-and-see rating, and the target price was adjusted from $13.00 to $11.00.
Barclays: Maintaining the Accolade (ACCD.US) rating, adjusted from a wait-and-see shareholding rating to a shareholding wait-and-see rating, and the target price was adjusted from $13.00 to $11.00.
Analysis
Price Target
No Data
